Invest in
Albert Labs

Click here to access our investor documents

Investor portal

Corporate Highlights

First biopharmaceutical company leveraging established, accelerated pathways to psychedelic-assisted therapies for patients with urgent, unmet needs across the UK, EU and other healthcare networks

Developing scalable solutions to generate clinical data through access to existing patient pools within world-leading research and clinical networks

Initial focus on treating cancer-related anxiety and depression before moving into broader mental health indications 

26 Apr 2023

Expansion of Drug Discovery and a Promising Pipeline

23 Nov 2022

Albert Labs Announces Private Placement

17 Nov 2022

Letter of Intent (LOI) for First-In-Human studies with iNGENū CRO

25 Oct 2022

Albert Labs Provides Corporate Update

20 Oct 2022

New International PCT Patent Application for scalable API manufacturing

11 Jul 2022

Albert Labs Appoints Two Industry Leading Directors

26 May 2022

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

16 May 2022

Albert Labs Granted Health Canada Licence

12 May 2022

Albert Labs’ Pre-Clinical Analytical and Toxicological Research Supports Company’s Forthcoming Studies

26 Apr 2022

Albert Labs Announces the Addition of Two Renowned Scientific Advisors to its Scientific Advisory Board (SAB)

30 Mar 2022

Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

10 Mar 2022

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange